The study's primary objective is to determine plasma and dialysis fluid concentrations in patients prescribed ceftazidime-avibactam as the standard treatment for their infection and requiring continuous venovenous hemodiafiltration (CVVHDF) as part of the standard treatment for acute or chronic renal failure. Secondarily, the study will evaluate the pharmacokinetics of ceftazidime-avibactam in these patients on CVVHDF. The study will also determine if the prescribed dose meets pharmacodynamic targets.
Study Type
OBSERVATIONAL
Enrollment
10
Patients will be started on 2.5 gm IV every 8 hours
Temple University Hospital
Philadelphia, Pennsylvania, United States
RECRUITINGCeftazidime plasma concentrations
mg/L
Time frame: At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)
Avibactam plasma concentrations
mg/L
Time frame: At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)
Ceftazidime effluent concentrations
mg/L
Time frame: At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)
Avibactam effluent concentrations
mg/L
Time frame: At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)
Maximum plasma concentration (Cmax)
mg/L
Time frame: At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)
Number of participants with adverse effects as a measure of safety
Measure of safety
Time frame: Days 1-30
Minimum plasma concentration (Cmin)
mg/L
Time frame: At hours post dose: 0, 2, 3, 4, 6, 8 on or after Day 2 of therapy (i.e. during the fourth dose)
Half-life (t1/2)
hours
Time frame: 8-hours
Clearance (Cl)
L/hr
Time frame: 8-hours
AUC 0 to 8 hours
mg\*hr/L
Time frame: 8-hours
Sieving Coefficient
SC
Time frame: 8-hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.